Navigation Links
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts

GIA announces the release of a comprehensive global report on Autoimmune Disease Therapeutics market. With the global incidence and prevalence of autoimmune diseases increasing, the market for drugs used in the treatment of these diseases is expected to flourish in the near future. Key factors driving this growth include increasing use of biologics, as against conventional treatment options. Priced higher than conventional drugs, biologic drugs continue to drive revenues for manufacturers. Besides, factors such as unmet medical needs and an extensive pipeline of drugs that bode superior efficacy, keep growth prospects optimistic.

San Jose, CA (PRWEB) June 30, 2009 -- Global market for Autoimmune Disease Therapeutics is projected to reach US$49.8 billion in 2015. Biologics emerged as the leading therapeutic option in the treatment of autoimmune diseases, owing to their superior efficacy compared to conventional small molecule drugs. Fueling growth are factors such as introduction of new products, enhanced access to drugs, and enhanced penetration of existing drugs. Access to biologics in the world's largest drug market, the US, is due primarily to the inclusion of Humira and Enbrel into Medicare Part D reimbursement in early 2006. New products that are being launched in the market provide expanded therapeutic options for patients who fail to respond to existing therapies. The United States represents the largest market for biological autoimmune disease therapeutics, while Europe represents the fastest growing market worldwide. Rheumatoid Arthritis represents the largest segment in the global market, while Crohn's Disease represents the fastest growing segment for biologics in the global autoimmune disease therapeutics market.

Lack of awareness on the disease and associated symptoms curbed accurate diagnosis of autoimmune diseases in the past. Symptoms of most autoimmune diseases are similar to that of certain common conditions that lead to wrong diagnoses, and consequently raise healthcare costs. Rapid advancement in the area of disease diagnostics is increasingly enabling physicians in making accurate diagnosis of various autoimmune diseases, which is resulting in a rise in number of patients diagnosed, and subsequently higher number of patients receiving therapy. Leading biological drugs in the present day treatment of autoimmune diseases include TNF inhibitors, such as Enbrel, Humira and Remicade. New products in the market, such as Rituxan and Orencia made significant inroads by addressing therapeutic needs not addressed by existing drugs.

The global marketplace is characterized by participants such as Abbott Laboratories, Amgen Inc., Bayer Schering Pharma AG, Biogen Idec Inc., Bristol-Myers Squibb Company, Chugai Pharmaceutical Co., Ltd., Elan Corporation, plc, Eli Lilly And Company, F. Hoffmann-La Roche AG, Genentech, Inc., GlaxoSmithKline plc, Johnson & Johnson, Inc., Merck Serono SA, Novartis AG, sanofi-aventis SA, Schering-Plough Corporation, Shire Pharmaceuticals Group plc., Teva Pharmaceuticals Industries Limited, UCB Pharma.

"Autoimmune Disease Therapeutics: A Global Strategic Business Report" announced by Global Industry Analysts, Inc. provides a comprehensive review of market trends, drivers, product profile, players, competition, recent developments, mergers, acquisitions, and other strategic industry activities. Analysis is presented for major geographic markets such as the US, Japan, Europe and Rest of World. Global and regional analytics are provided for product segments such as Rheumatoid Arthritis, Multiple Sclerosis, Psoriasis, Crohn's Disease and Other Autoimmune Diseases.

For more details about this comprehensive market research report, please visit -

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 800 people worldwide and publishes more than 1100 full-scale research reports each year. Additionally, the company also offers thousands of smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.

Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press (at) StrategyR (dot) com
Web Site


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
Related Image:
Global Autoimmune Disease Therapeutics Market to Reach $50 Billion by 2015, According to a New Report by Global Industry Analysts
(Date:11/24/2015)... ... , ... Young patients with a wide variety of dental needs can now ... Lele, who are pediatric dentists in Tucson, AZ . Unlike traditional treatment options ... causes minimal discomfort and bleeding to the patient during treatment and the following recovery ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Black Friday sale a week early, offering 40% off select bras and underwear ... apparel industry through both mobile fit technology and the latest fashion, quickly becoming ...
(Date:11/24/2015)... ... November 25, 2015 , ... Catalent Pharma Solutions, the ... consumer health and global clinical supply services, today announced that Dr. Christine Milligan, ... East Asia Conference, to be held at the InterContinental Seoul COEX Hotel, Seoul, ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... when it comes to several aspects of orthopedic care. They have received recognition ... surgeries and general orthopedic care. , Becker's Hospital Review selected hospitals for ...
(Date:11/24/2015)... , ... November 24, 2015 , ... It takes only ... a business, it is critical that the first impression be positive and reflects business ... not likely to buy anything or want to return. They will also share their ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... November 24, 2015   ... dietician deliver s advice and insights on ... More than 50% of Dubai ... healthy according to the DHA   femMED launches comprehensive solutions ...    Dubai residents are not consuming enough to ...
(Date:11/24/2015)... Nov. 24, 2015 Abaxis, Inc. (NasdaqGS: ... and consumables for the medical, research, and veterinary markets ... Financial Officer, will present at the 27 th ... 2015 at 11:30 a.m. ET. The conference will be ... New York City . Abaxis, ...
(Date:11/24/2015)... Edelris announce today that they have out-licensed to ... UCBL and ENS-Lyon on a new treatment to cure Hepatitis ... B virus (HBV) infection is a major public health problem ... to 40% of them being at risk of developing chronic ... an effective preventive vaccine, the HBV infection is still rampant ...
Breaking Medicine Technology: